TIDMMXCT TIDMTTM
RNS Number : 8666B
MaxCyte, Inc.
15 June 2021
MaxCyte Adds Two New Non-Executive Directors to Its Board
Gaithersburg, Maryland - 15 June 2021: MaxCyte (LSE: MXCT,
MXCN), a leading provider of platform technologies for cell
engineering, today announced the appointment of Rekha Hemrajani and
Yasir Al-Wakeel, BM BCh, to the company's board of directors as
non-executive directors with immediate effect. Ms. Hemrajani is
appointed as a non-executive member of the Compensation Committee
and Dr. Al-Wakeel is appointed as a non-executive member of the
Audit Committee.
"With their expertise in business and corporate development as
well as finance combined with deep life sciences industry
experience, Ms. Hemrajani and Dr. Al-Wakeel bring valuable insights
and perspective to our board," said Doug Doerfler, president and
CEO of MaxCyte. "We are honored to have them join us as we advance
the next-generation of cell therapy discovery, development and
commercialisation."
Ms. Hemrajani is a senior executive with more than 20 years of
biopharmaceutical industry experience and has extensive expertise
in all aspects of corporate strategy, corporate and business
development, financing, and strategic planning. She currently
serves as chief executive officer (part time) and director of Jiya
Acquisition Corp (NASDAQ: JYAC), where she led the $100 million
initial public offering (IPO). Ms. Hemrajani has held senior
management positions at numerous listed biopharmaceutical
companies, including president, chief executive officer and
director of Aravive, Inc (NASDAQ: ARAV), chief financial officer
and chief operating officer of Arcus Biosciences, Inc. (NYSE:
RCUS), and chief operating officer of FLX Bio, Inc. (NASDAQ: RAPT).
Previously, she was vice president, head of Licensing and Mergers
& Acquisitions Group for Onyx Pharmaceuticals (NASDAQ: ONXX
sold to Amgen for $10.4 billion), vice president of business
development of Exelixis (NASDAQ: EXEL), and on the healthcare
investment banking teams of Lehman Brothers, Inc. and Credit Suisse
First Boston. She is currently a non-executive director of ALX
Oncology Holdings (NASDAQ: ALXO).
Ms. Hemrajani received a Master of Management from the J.L.
Kellogg Graduate School of Management at Northwestern University,
and a B.S. in economics and computer science from the University of
Michigan.
Dr. Al-Wakeel currently serves as chief financial officer and
head of corporate development for Kronos Bio (NASDAQ: KRON), where
he oversees the company's financial planning and accounting,
investor relations, and business development activities. He was
instrumental in the company's $288 million IPO. He previously
served as chief financial and strategy Officer at Neon Therapeutics
(NASDAQ: NTGN) where he played a key role in the company's public
and private financings as well as its eventual sale to BioNTech.
Prior to that, he was chief financial officer and head of corporate
development at Merrimack Pharmaceuticals (NASDAQ: MACK), where he
helped shape and execute the company's refocused business strategy,
culminating in a $1 billion asset sale to Ipsen. Prior to those
roles, Dr. Al-Wakeel served in senior roles in equity research and
corporate finance at Credit Suisse focused on the biotechnology
sector. During his tenure in corporate finance, he was involved in
more than $30 billion in strategic and financial transactions for
the firm.
Dr. Al-Wakeel, began his career as a practicing physician,
holding both clinical and academic medical posts in the United
Kingdom. He holds a BM BCh (Doctor of Medicine and Surgery) from
Oxford University and an M.A. in theology from Cambridge
University.
Grant of options
As is customary for US companies, upon appointment, Ms.
Hemrajani and Dr. Al-Wakeel have each been granted 80,700 options
over common stock, $0.01 par, of the Company ("Options"). These
Options vest over three (3) years, with initial vesting of 1/3(rd)
of the total after twelve (12) months, and the remainder vesting
monthly over the following twenty-four (24) months. The Options
have an exercise price of GBP8.92, equal to the closing price of
Maxcyte's stock on 14 June 2021.
Ms. Hemrajani, 52, is, or has been in the previous five years, a
director or partner of the following companies:
Current appointment Past appointment
Jiya Acquisition Corp Aravive, Inc
ALX Oncology Holdings Inc Adverum Biotechnologies, Inc
Ravinia Consulting Inc
Hemmo Pharma LLP
Hemmo Pharmaceuticals Private
Limited
The Company confirms that there is no further information to be
disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the
AIM Rules for Companies.
Dr. Al-Wakeel, 39, is, or has been in the previous five years, a
director or partner of the following companies:
Current appointment Past appointment
Taha Collective, Inc Boston Life Sciences, LLC
The Company confirms that there is no further information to be
disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the
AIM Rules for Companies.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Rekha Hemrajani
Yasir Al-Wakeel
==================================================================== ===========================================
2 Reason for the notification
=================================================================================================================
a) Position/status Non-Executive Directors
==================================================================== ===========================================
b) Initial notification/Amendment Initial notification
==================================================================== ===========================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=================================================================================================================
a) Name MaxCyte, Inc.
==================================================================== ===========================================
b) LEI 54930053YHXULRFCU991
==================================================================== ===========================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
=================================================================================================================
a) Description of Options over common stock , $0.01 par,
the financial of the Company
instrument, type
of instrument
==================================================================== ===========================================
b) Identification US57777K1060
Code
==================================================================== ===========================================
c) Nature of the Grant of Options
transaction
==================================================================== ===========================================
d) Price(s) and volume(s) Rekha Hemrajani - 80,700 Options at an
exercise price of GBP8.92
Yasir Al-Wakeel - 80,700 Options at an
exercise price of GBP8.92
==================================================================== ===========================================
e) Aggregated information N/A
- Aggregated volume N/A
- Price N/A
==================================================================== ===========================================
f) Date of the transaction 14 June 2021
==================================================================== ===========================================
g) Place of the transaction London Stock Exchange, AIM Market (XLON)
==================================================================== ===========================================
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialisation. MaxCyte's existing
customer base ranges from large biopharmaceutical companies,
including all of the top 10, and 20 of the top 25, pharmaceutical
companies based on 2020 global revenue, to hundreds of
biotechnology companies and academic centres focused on
translational research. MaxCyte has granted 13 strategic platform
licences to commercial cell therapy developers. Including these
strategic platform licences, MaxCyte has granted pre-clinical and
clinical licences to academic and industry customers covering over
an estimated 140 programmes, of which an estimated 100 programmes
are for clinical use. MaxCyte was founded in 1998 and is
headquartered in Gaithersburg, Maryland, US. For more information,
visit www.maxcyte.com .
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Accounting Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
----------------------
Joint Corporate Broker
Numis Securities Limited
James Black / Duncan Monteith /
Matthew O'Dowd +44 (0)20 7260 1000
----------------------
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison /
Samira Essebiyea
Corporate Broking
Nick Adams +44 (0) 20 7710 7600
----------------------
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh + 44 (0)203 709 5700
----------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUSVRRARUNAUR
(END) Dow Jones Newswires
June 15, 2021 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
